Introduction

Mycobacterium avium complex (MAC) is a group of nontuberculous mycobacteria usually causing disease in individuals with immunodeficiency or structural lung disease [1]. Defects in the interleukin-12/interferon-gamma (IFN-γ) pathway and autoantibodies against IFN-γ have been associated with severe nontuberculous mycobacteria (NTM) infections. Consequently, disseminated NTM infections should prompt investigations for immunodeficiency. Herein, we report a case of a treatment refractory and ultimately disseminated and fatal Mycobacterium avium complex infection in a 71-year-old woman of Thai origin. Simultaneously, she had recurrent Salmonella kentucky cultured from stool samples and chronic perianal HSV-2 lesions. Late in the course of disease, anti–IFN-γ autoantibodies were demonstrated. Clinical studies investigating immunomodulating therapy and treatment among patients with anti-IFN-γ autoantibodies are lacking and, in this case, treatment seemed of a more palliative nature.

Case

A 71-year-old female, originally from Thailand, presented with fatigue, weight loss (8–10 kg), 3–4 daily loose stools, night sweats, and recurring fever. She had a medical history of diabetes mellitus (type 2), hypertension, dyslipidaemia, and paroxysmal atrial fibrillation and was a never smoker. The patient had lived in Denmark for 23 years, and during a recent 3-year stay in Thailand, she was diagnosed with tuberculosis and treated only for a shorter period for unknown reasons. In March 2017, initial physical examination revealed a pale, cachectic woman with universal lymphadenopathy. Computed-tomography (CT) scan showed a small, apical cavity in the right lung as well as small noduli and a discrete infiltrate in the left lower lobe. A cervical lymph node biopsy showed lymphoglandular bodies with multiple mature lymphocytes, but no sign of granulomas. An HIV test result was negative.

Microscopy of sputum was positive for acid fast bacilli and antituberculosis treatment was initiated. However, MAC (unnamed subspecies) was subsequently cultured (Fig. 1) and the treatment was changed to a standard MAC regimen with rifampicin, ethambutol and clarithromycin. Four months later, the treatment was...
discontinued due to lack of pulmonary symptoms. In November 2017, a positron emission tomography–computed tomography (PET/CT) scan showed progression of infiltrates including a new infiltrate in the left upper lobe as well as enhancement in multiple lymph nodes below and above the diaphragm. Endobronchial ultrasound-guided bronchoscopy revealed fibrotic-looking tissue and MAC was again cultured from sputum and still susceptible to macrolides. Thus, MAC treatment was reinitiated. Rifampicin was replaced by rifabutin due to in vitro drug resistance. However, five months later, the treatment was paused for one and a half months because of elevated liver enzymes (alkaline phosphatase 1080 U/L (reference 35–105) and ALAT 198 U/L (reference [10–45])). Imaging of the liver showed hepatomegaly and fibrosis as well as irregularity of the bile ducts suggesting primary biliary cirrhosis. Moreover, antimitochondrial antibodies were measured, but due to the clinical status of the patient, a liver biopsy was never performed. The suspicion of primary biliary cirrhosis was never confirmed.

In June 2018, admission of the patient was warranted due to severe diarrhea with dehydration and continuous weight loss. Treatment was paused for a couple of weeks. Eventually, oral administration of clarithromycin was changed to intravenous for ten days and parenteral nutrition was initiated, which improved the clinical status significantly. The patient continued with oral MAC treatment and four months of intravenous amikacin.

Immunological examination showed severely reduced concentration of CD4 T-cells 0.26 × 10⁹/L (Table 1). CD8 T-cell count was within normal range, but the distribution of CD8 T-cell subsets were distributed toward terminal differentiation 47% (defined as CD57pos) and HLA-DR expression was upregulated on both CD4 and CD8 T-cells (51% and 81% expressed HLA-DR) indicating immune activation. The fraction of CD4 recent thymic emigrants (CD45ROnegCD4RAposCD31pos) was normal but the overall concentration was low presumably secondary to the reduced total CD4 T-cell concentration. IgA, IgE and IgG classes were all significantly

---

Fig. 1. Overview of hemoglobin, albumin and weight (upper figure) and leukocytes, lymphocytes and C-reactive protein (lower figure) during nontuberculous mycobacterial treatment throughout the entire course of disease. Abbreviations: ETH, ethambutol. CLR, clarithromycin. RIF, rifampicin. RIB, rifabutin. CRP, C-reactive protein.
Diseases (MSMD) [6]. The undetectable IFN-γ production was initially interpreted as possibly secondary to severe CD4 T cell lymphopenia. However, when screening for autoantibodies (CM-CSF, IFNα, IFN-γ, IL-10, IL-1α and IL-6) severely elevated levels of presumably neutralizing IL-1α- and IFN-γ-autoantibodies were detected [7]. Subsequently, interferon gamma-1b 60 µg subcutaneous thrice weekly was commenced.

Both clinical and paraclinical parameters continued to improve after treatment intensification. Likewise, a PET/CT showed significant regression of all infiltrates in thorax. However, after eight months of clinical improvement, the patient presented with lower back pain with radiation to the lower extremities and clinical signs of infection. MRI and PET/CT of columna were unable to exclude spondylodiscitis, but a percutaneous biopsy from the left pedicle of L5 including culture (including mycobacterial), 16S/18S PCR and pathology did not establish a diagnosis. Meanwhile, *Candida lusitaniae* was found in blood cultures, and in July 2019, a biopsy from a swollen lymph node was positive for acid fast bacilli. Once again, HRCT showed progression in infiltrates (Fig. 2). The treatment was subsequently changed to palliative care after twenty-nine months of active treatment and the patient died two weeks later.

During the entire course of disease, the patient suffered from severe chronic perianal HSV-2 skin lesions. The chronic diarrhoea was examined with intestinal biopsies, which showed lymphocyte and plasma cell infiltration, but celiac antibodies were not detected. *Salmonella kentucky*, was cultured from feces twice. Though, the cultures were made a year a part, the patient might have contracted the bacteria in Thailand. Also, MAC was cultured twice in the blood. In addition, several different skin lesions were sporadically occurring. Histological examination of an erythema nodosum looking lesion was identified as leukocytoclastic vasculitis and another skin lesion contained granulomatous inflammation and giant cells.

**Discussion**

We describe a case of a treatment refractory and ultimately disseminated and fatal MAC infection in a 71-year-old woman ofThai origin. Simultaneously, she had recurrent *Salmonella kentucky* cultured from stool samples and chronic perianal HSV-2 lesions. Late in the course of disease, anti-IFN-γ autoantibodies were demonstrated. Typically, MAC infections are considered either a local pulmonary infection in patients with structural lung damage, or a disseminated opportunistic infection associated with HIV or other immunodeficiencies [1]. Consequently, immunodeficiency should always be investigated in disseminated infections. In this case, the patient was suspected of a localized pulmonary infection for a long period, while an immunodeficiency due to anti–IFN-γ autoantibodies was found relatively late in the course of disease. The QuantiFERON®-TB was indeterminate, as it has been reported for several cases [3], and it has been suggested that the autoantibodies neutralize IFN-γ secreted from the lymphocytes. Consequently, an indeterminate QuantiFERON®-TB test result due to undetectable or extremely low levels of IFN-γ support the diagnosis of anti–IFN-γ autoantibodies [8].

Since the beginning of the millennium, several cases of disseminated infections with NTM in the presence of high titers of anti-IFN-γ autoantibodies have been described among HIV-negative patients [5,9–12]. The prevalence of this immunodeficiency, defined ‘anti–IFN-γ autoantibody-associated immunodeficiency syndrome’, is unknown and is probably underdiagnosed [2,4]. The syndrome is most often reported among midlife females of East Asian heritage [2,5]. Yet, the patient was somewhat older in this case. The mechanisms and triggers of the disease are not clearly understood [4], but the syndrome has been associated with HLA-DRB1 and HLA-DQB1 [13–15]. Moreover, molecular mimicry has been proposed as a

---

### Table 1

Overview of immunological analyses.

|                          | Results   | Reference values | Unit          |
|--------------------------|-----------|------------------|---------------|
| **Leukocytes**           |           |                  |               |
| Lymphocytes              |           |                  |               |
| B cells, CD19<sup>a</sup> | 0.18      | 0.09–0.57        | 10<sup>9</sup>/L |
| T cells, CD3<sup>a</sup>  | 0.59      | 0.69–2.70        | 10<sup>9</sup>/L |
| CD4<sup>+</sup> T-cells   | 0.26      | 0.39–1.70        | 10<sup>9</sup>/L |
| CD8<sup>+</sup> T-cells   | 0.30      | 0.19–1.03        | 10<sup>9</sup>/L |
| Ratio CD4/CD8             | 1.1       |                  |               |
| RTE of CD4-T-cells       | 7.0       | 6.4–51.0<sup>b</sup> | %           |
| NK cells, CD16/56<sup>a</sup> | 0.50   | 0.08–0.56        | 10<sup>9</sup>/L |

**Immunoglobulins**

|        |           |                  |               |
|--------|-----------|------------------|---------------|
| IgA    | 653–1412  | 70–430           | mg/dL         |
| IgG    | 2537–2874 | 610–1490         | mg/dL         |
| IgG1   | 1730      | 280–800          | mg/dL         |
| IgG2   | 516       | 120–570          | mg/dL         |
| IgG3   | 156       | 24–125           | mg/dL         |
| IgG4   | 486       | 5.2–125          | mg/dL         |
| IgM    | 80–99     | 39–208           | mg/dL         |
| IgE    | 1286–1480 | 0–150            | kIU/L         |

**Somatic hypermutation of expressed immunoglobulin kappa light chain genes**

|          |           |                  |               |
|----------|-----------|------------------|---------------|
| Classical activation | 164       | > 69%            | % of positive control |
| Lectin activation    | 175       | > 1%             | % of positive control |
| Alternative activation | 164     | > 30%            | % of positive control |

**Lymphocyte stimulation**

|                     |           |                  |               |
|---------------------|-----------|------------------|---------------|
| Pokeweed Mitogen    | 67        |                  | % of positive control |
| Anti-CD3/CD28/CD2    | 94        |                  | % of positive control |

**IFN-γ /IL-12 axis function**

|                  | Stimuli | LPS | LPS+IFN-γ |
|------------------|---------|-----|-----------|
| TNF-α (pg/mL)    | Control 1 | 158 | 994       |
|                  | Control 2 | 269 | 1893      |
|                  | Patient   | 31  | 190       |
| IL-12p70 (pg/mL) | Control 1 | 288 | 1734      |
|                  | Control 2 | 434 | 2357      |
|                  | Patient   | 229 | 247       |
|                   | Stiulii   | PHA | PHA+IL-12 |
| IFN-γ (pg/mL)    | Control 1 | 748 | 5323      |
|                  | Control 2 | 956 | 5660      |
|                  | Patient   | undetectable | undetectable |

**Abbreviations:** CD, cluster of differentiation. RTE, recent thymic emigrants. NK, natural killer. Ig, immunoglobulin. IFN, interferon. IL, interleukin. TNF, tumor necrosis factor.

<sup>a</sup> Reference values: http://www.mayomedicallaboratories.com/test-catalog.

<sup>b</sup> Lumines kit used for measuring Cytokine production: ProcartaPlex Multiplex Immunoassay, ThermoFisher.
potential mechanism of autoantibody production [16]. Prior to disease onset, most of the patients are immunocompetent [12].

The patient in our case presented with classical symptoms, such as weight loss, fever, reactive cutaneous lesions, and generalized lymphadenopathy [3]. In addition, the patient presented with Herpes and Salmonella infections as previously described in patients with IFN-γ autoantibodies [2,3,5] and in patients with inborn defects in the IL-12/IFN-γ pathway, the so-called ‘Mendelian susceptibility to mycobacterial disease’, i.e., impaired IFN-γ receptors, downstream signaling or production of IFN-γ [17]. Tuberculosis as well as more rare infections as *Talaromyces marneffei* among patients with anti-IFN-γ autoantibodies have been described in several reports although more infrequently than NTM [2,5,18]. These opportunistic infections are most likely secondary to the immunodeficiency.

Moreover, we observed that the patient had a low CD4 T-cell count, and elevated levels of IgA and IgE as well as anti-IL-1α, anti-actin and anti-mitochondrial antibodies, which to our knowledge has not been described as a common finding in this syndrome. In addition, involvement of the liver and intestines was prominent. Whether this was due to antibiotic toxicity or live infiltration with MAC and subsequent immune reconstitution inflammatory syndrome rather than primary biliary cirrhosis remains speculative.

The patient was treated for a very long period and was for shorter periods in clinical improvement. During initial treatment, antibiotics were discontinued after only four months, suggesting that many clinicians are unaware that treatment is recommend for at least one year after culture-converted. As a matter of fact, the disease seemed to progress with dissemination of MAC outside the lungs. At the moment, the evidence about treatment of patients with anti-IFN-γ antibodies remains sparse and cure is rarely achieved [2,4]. Anti-microbial therapy is most often insufficient with slow remission or frequent relapses [19]. Adjunctive treatment with rituximab, IFN-γ, intravenous immunoglobulin, corticosteroids, cyclophosphamide, and plasmapheresis have been tried [2,3]. In hindsight, the patient may not have benefitted from the IFN-γ therapy due to inactivation by the autoantibodies although this strategy has previously been suggested in the management of patients with anti-IFN-γ autoantibodies [20]. Yet, we do not know the exact epitope for the autoantibodies and the binding capacity. Unfortunately, we did not fully understand the clinical presentation until late in the course of disease. Rituximab is the most studied immunomodulatory drug among patients with anti-IFN-γ autoantibody-associated immunodeficiency syndrome, and was considered during the course of disease, but was withheld, awaiting effect of antibiotics. Although evidence is still needed, rituximab appears to improve clinical outcomes by decreasing both titers and neutralizing capacity of the antibodies [2–4]. However, it is still unclear what the preferable drugs are and what the optimal strategy is, e.g., supporting the immune system and/or on inhibiting the synthesis of autoantibodies. Evidence about the ideal treatment including dosing and duration and the clinical implications of reducing anti-IFN-γ antibodies titers is needed.

In conclusion, disseminated NTM infections should always prompt investigations for immunodeficiency including examination of the IL-12/IFN-γ pathway. Interestingly, this case had several other immunological abnormalities besides anti-IFN-γ autoantibodies. Clinical management of patients with NTM and anti-IFN-γ autoantibodies is exceptionally challenging, as there is little evidence to support the treatment, and we recommend that the patients are managed at specialized clinics.

**Author statement**

VND wrote the first draft and did literature research with major inputs from BUN. The conception and design of the case report was conducted by VND, BUN and ABA. All authors critically revised the article for important intellectual content. The patient was treated by ABA. All authors approve of the final version of the article.

**Conflicts of interest**

None to declare.

**Consent**

Informed consent was given from the next of kin.
Ethical approval

In our setting, ethical approval for case reports are not required if informed consent is given.

References

[1] Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4):367–416.

[2] Valour F, Perpoint T, Sénéchal A, Kong X-F, Bustamante J, Ferry T, et al. Interferon-γ autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis 2016;22(6):1124–6.

[3] Hase I, Morimoto K, Sakagami T, Ishii Y, van Ingen J. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review. Diagn Microbiol Infect Dis 2017;88(4):308–15.

[4] Chawansuntati K, Rattanathammethee K, Wipasa J. Minireview: insights into anti-interferon-γ autoantibodies. Exp Biol Med 2021;246(7):790–5.

[5] Hong GH, Ortega-Villa AM, Hunsberger S, Chetchotisakd P, Anunnatsiri S, Moorsikapun P, et al. Natural history and evolution of anti-interferon-γ autoantibody-associated immunodeficiency syndrome in Thailand and the United States. Clin Infect Dis 2020;71(1):53–62.

[6] Feinberg J, Fieschi C, Doffinger R, Feinberg M, Leclerc T, Boisson-Dupuis S, et al. Naturally occurring anti-IFN-gamma autoantibodies underlie disseminated nontuberculous mycobacterial infections in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood 2013;121(8):1357–66.

[7] Lin C-H, Chang S-W, Chu C-C, Chan JFW, Kong X-F, et al. Anti-IFN-γ autoantibodies are strongly associated with HLA-DRB1*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia. J Allergy Clin Immunol 2016;137(3):945–948.e8. 945-8.e8.

[8] Ku C-L, Lin C-H, Chang S-W, Chi C-Y, Shih H-P, Ding J-Y, Lo C-C, Wang S-Y, et al. Identification of a major epitope by anti-interferon-γ autoantibodies in patients with mycobacterial disease. Nat Med 2016;22(9):994–1001.

[9] Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol 2014;26(6):454–70.

[10] Guo J, Ning X-Q, Ding J-Y, Zheng Y-Q, Shi N-N, Wu F-Y, et al. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections. J Exp Med 2020;217(12).

[11] Chetchotisakd P, Anunnatsiri S. Linezolid in the treatment of disseminated nontuberculous mycobacterial infection in anti-interferon-gamma autoantibody-positive patients. Southeast Asian J Trop Med Public Health 2014;45(5):1125–31.

[12] Harada M, Furuhashi K, Karamay M, Suzuki Y, Hozumi H, Enomoto N, et al. Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN-γ autoantibody associated disseminated nontuberculous mycobacterial infection. J Infect Chemother 2021;27(2):373–8.